VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+9.34%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$612M
AUM Growth
+$115M
(+23%)
Cap. Flow
+$92.1M
Cap. Flow
% of AUM
15.06%
Top 10 Holdings %
Top 10 Hldgs %
8.98%
Holding
532
New
97
Increased
238
Reduced
88
Closed
80
Top Buys
| 1 |
Telecom Argentina
TEO
|
$2.3M |
| 2 |
Methanex
MEOH
|
$1.47M |
| 3 |
The GEO Group
GEO
|
$1.43M |
| 4 |
EQM
EQM Midstream Partners, LP
EQM
|
$1.42M |
| 5 |
Vale
VALE
|
$1.35M |
Top Sells
| 1 |
Oxford Square Capital
OXSQ
|
$2.69M |
| 2 |
MPLX
MPLX
|
$1.51M |
| 3 |
MDCO
Medicines Co
MDCO
|
$982K |
| 4 |
Gladstone Investment Corp
GAIN
|
$839K |
| 5 |
CELG
Celgene Corp
CELG
|
$712K |
Sector Composition
| 1 | Financials | 20.46% |
| 2 | Real Estate | 16.88% |
| 3 | Energy | 14.34% |
| 4 | Healthcare | 10.85% |
| 5 | Materials | 9.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Travere Therapeutics
TVTX
$1.93B
| $632K | 0.1% |
44,525
+8,428
| +23% | +$120K |
|
177
Exelixis
EXEL
$10.2B
| $631K | 0.1% |
35,810
+632
| +2% | +$11.1K |
|
178
Gilead Sciences
GILD
$143B
| $631K | 0.1% |
9,704
-1,328
| -12% | -$86.4K |
|
179
Ligand Pharmaceuticals
LGND
$3.25B
| $627K | 0.1% |
9,642
-705
| -7% | -$45.8K |
|
180
United Therapeutics
UTHR
$18.1B
| $627K | 0.1% |
7,121
-1,735
| -20% | -$153K |
|
181
Vanda Pharmaceuticals
VNDA
$272M
| $626K | 0.1% |
38,136
-9,334
| -20% | -$153K |
|
182
Alnylam Pharmaceuticals
ALNY
$59.2B
| $625K | 0.1% |
5,424
-4,464
| -45% | -$514K |
|
183
Sarepta Therapeutics
SRPT
$1.96B
| $624K | 0.1% |
4,833
-961
| -17% | -$124K |
|
184
Neurocrine Biosciences
NBIX
$14.3B
| $620K | 0.1% |
5,771
-2,479
| -30% | -$266K |
|
185
Acadia Pharmaceuticals
ACAD
$4.26B
| $616K | 0.1% |
14,396
-14,167
| -50% | -$606K |
|
186
Ionis Pharmaceuticals
IONS
$9.76B
| $611K | 0.1% |
10,116
-1,040
| -9% | -$62.8K |
|
187
Incyte
INCY
$16.9B
| $608K | 0.1% |
6,967
-1,944
| -22% | -$170K |
|
|
ONC
188
BeOne Medicines Ltd. American Depositary Shares
ONC
$37.6B
| $601K | 0.1% |
3,625
+1,470
| +68% | +$244K |
|
189
Halozyme
HALO
$8.76B
| $596K | 0.1% |
33,612
-10,434
| -24% | -$185K |
|
190
Enanta Pharmaceuticals
ENTA
$189M
| $592K | 0.1% |
9,576
+1,497
| +19% | +$92.5K |
|
191
Quince Therapeutics
QNCX
$86.5M
| $592K | 0.1% |
+10,553
| New | +$592K |
|
|
IMGN
192
DELISTED
Immunogen Inc
IMGN
| $587K | 0.1% |
115,075
-12,521
| -10% | -$63.9K |
|
|
PTLA
193
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $579K | 0.09% |
24,255
-2,655
| -10% | -$63.4K |
|
|
RDUS
194
DELISTED
Radius Health, Inc.
RDUS
| $575K | 0.09% |
28,509
-2,989
| -9% | -$60.3K |
|
|
EPZM
195
DELISTED
Epizyme, Inc
EPZM
| $572K | 0.09% |
23,272
+1,552
| +7% | +$38.1K |
|
|
AKCA
196
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $560K | 0.09% |
33,059
+21,948
| +198% | +$372K |
|
197
Precision BioSciences
DTIL
$59.8M
| $556K | 0.09% |
+1,335
| New | +$556K |
|
|
SWTX
198
DELISTED
SpringWorks Therapeutics
SWTX
| $549K | 0.09% |
+14,253
| New | +$549K |
|
199
Lexicon Pharmaceuticals
LXRX
$396M
| $545K | 0.09% |
131,286
+8,632
| +7% | +$35.8K |
|
|
PRVB
200
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $523K | 0.09% |
+35,118
| New | +$523K |
|